PMID- 18081737
OWN - NLM
STAT- MEDLINE
DCOM- 20080331
LR  - 20181201
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 27
IP  - 5
DP  - 2008 Mar 1
TI  - Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or 
      nonresponsive to peginterferon alfa-2b/ribavirin.
PG  - 433-40
AB  - BACKGROUND: Peginterferon alfa-2a/ribavirin treatment resulted in fewer 
      incidences of depression and flu-like symptoms than that of standard 
      interferon/ribavirin, whereas peginterferon alfa-2b/ribavirin and standard 
      interferon/ribavirin treatment resulted in similar incidences of these adverse 
      events (AEs). AIM: To assess the efficacy and safety of peginterferon 
      alfa-2a/ribavirin in genotype 1-infected patients treated for up to 12 weeks with 
      peginterferon alfa-2b/ribavirin but not achieving early virologic response (EVR) 
      (non-EVR) or nontolerant (NT) because of depression, fatigue, flu-like symptoms, 
      or injection-site reactions. METHODS: Nontolerants were treated for an additional 
      36 weeks and non-EVRs for an additional 60 weeks with peginterferon alfa-2a (180 
      microg/week)/ribavirin (1000/1200 mg/day). Patients with detectable HCV RNA after 
      12 weeks were discontinued. RESULTS: Of 25 NTs, 23 (92%) were HCV-RNA negative 
      after 12 weeks on peginterferon alfa-2a/ribavirin and 14 (56%) achieved sustained 
      virologic response. Of 32 non-EVRs to peginterferon alfa-2b/ribavirin, four (13%) 
      achieved EVR with peginterferon alfa-2a/ribavirin and one (3%) achieved sustained 
      virologic response. Four non-EVRs and 0 NTs were withdrawn for AEs; 26 (81%) and 
      24 (96%), respectively, completed peginterferon alfa-2a/ribavirin treatment or 
      were withdrawn for insufficient response at week 12. In NTs, depression, fatigue, 
      flu-like symptoms, and injection-site reactions declined during treatment. 
      CONCLUSION: Most patients who did not tolerate peginterferon alfa-2b/ribavirin 
      because of AEs, and who completed the full 36-week course of peginterferon 
      alfa-2a/ribavirin treatment, achieved sustained virologic response.
FAU - Rustgi, V K
AU  - Rustgi VK
AD  - Liver Transplantation Unit, Georgetown University Medical Center, Washington, DC, 
      USA. hepgi@aol.com
FAU - Esposito, S
AU  - Esposito S
FAU - Hamzeh, F M
AU  - Hamzeh FM
FAU - Shiffman, M L
AU  - Shiffman ML
LA  - eng
SI  - ClinicalTrials.gov/NCT00087568
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071210
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (RNA, Viral)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - G8RGG88B68 (peginterferon alfa-2b)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Adult
MH  - Anemia/chemically induced
MH  - Antiviral Agents/adverse effects/*therapeutic use
MH  - Depression/psychology
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - *Drug Tolerance
MH  - Female
MH  - Hepacivirus/drug effects/genetics
MH  - Hepatitis C, Chronic/*drug therapy/genetics
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Neutropenia/chemically induced
MH  - Polyethylene Glycols/adverse effects/*therapeutic use
MH  - RNA, Viral/drug effects/genetics
MH  - Recombinant Proteins
MH  - Ribavirin/adverse effects/*therapeutic use
MH  - Surveys and Questionnaires
MH  - Thrombocytopenia/chemically induced
MH  - Time Factors
MH  - Viral Load
EDAT- 2007/12/18 09:00
MHDA- 2008/04/01 09:00
CRDT- 2007/12/18 09:00
PHST- 2007/12/18 09:00 [pubmed]
PHST- 2008/04/01 09:00 [medline]
PHST- 2007/12/18 09:00 [entrez]
AID - APT3587 [pii]
AID - 10.1111/j.1365-2036.2007.03587.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2008 Mar 1;27(5):433-40. doi: 
      10.1111/j.1365-2036.2007.03587.x. Epub 2007 Dec 10.